The Rising Role of Modeling in Oncology - From Translation to Confirmation
ACoP11 Pre-Conference: The Rising Role of Modeling in Oncology - From Translation to Confirmation (separate registration required) - Includes pre-conference poster session
Co-Chairs: Heather Vezina (BMS), Peter Bonate (Astellas) and Mary Spilker (Pfizer)
Pre-Conference Session 1: Current Modeling Practices in Oncology
Translation in Oncology: Current Practices and Impact of PKPD Modeling on Guiding Decisions an Iterative Learning in Early Trials
Owen Jones (Astrazeneca)
Tumor Dynamic Modeling and Overall Survival Predictions
Rene Bruno (Roche)
What can Pharmacometricians Learn from Mathematical Oncology?
Kristin Swanson (Arizona State University)
Pre-Conference Session 2: Emerging Modeling Approaches in Oncology
Model Based Meta-Analysis: Application to Drug Development Decisionmaking in Oncology
Marion Bouillon-Pichault (Bristol Myers Squibb)
Integration of Omics Data Sources to Inform Mechanistic Modeling of Immuno-Oncology Therapies
Andrzej Kierzek (Certara)
Approaches to Predict and Understand Drug Efficacy from Multi-omics Data: from Machine Learning to Logic Models
Julio Saez-Rodriguez (Heidelberg Unversity)
Pre-Conference Poster Session
Session 3: The FDA's MIDD Pilot Program and Oncology Case Studies
Role of Modeling in Oncology - MIDD Pilot Program Experience
Rajanikanth Madabushi (FDA)
The Use of Target Receptor Occupancy as an Exposure Endpoint to Guide Drug Development of Mosunetuzumab, a Bispecific for Non-Hodgkins Lymphoma